← Back to feed
Startups

Converge Bio raises $25M Series A — 4.5x protein yields, Bessemer + Meta/OpenAI/Wiz execs back it

Converge Bio closed a $25M oversubscribed Series A led by Bessemer Venture Partners with TLV Partners, Saras Capital and Vintage Investment Partners participating; execs from Meta, OpenAI and Wiz joined as individual LPs. The company builds generative models trained on DNA, RNA and protein sequence data, with three commercial systems: antibody design, protein yield optimization, and biomarker/target discovery. Traction: 40+ programs with over a dozen pharma/biotech customers across the US, Canada, Europe and Israel, expanding into Asia. Case studies include a 4-to-4.5x protein-yield boost in a single computational pass, and antibodies with single-nanomolar binding affinity. Headcount grew from 9 in Nov 2024 to 34 today. Prior seed was $5.5M in 2024. CEO Dov Gertz founded the company.

startupsdrug-discoverybessemerseries-abiotech

Why it matters

Converge Bio is the cleanest post-GPT-Rosalind signal that the AI-for-biology stack is beginning to bifurcate: OpenAI goes broad and regulated, specialist startups go deep on a single pipeline step (antibody design, yield optimization) with direct pharma contracts. Bessemer backing plus on-paper execs from Meta, OpenAI and Wiz suggest the network is choosing to place bets on vertical AI biotech rather than general-purpose LLM wrappers. 34 employees and 40 programs is unusually productive for a Series A — the efficiency argument for AI-native biotech now has live numbers.

Impact scorecard

7.1/10
Stakes
7.5
Novelty
7.0
Authority
8.0
Coverage
6.0
Concreteness
9.0
Social
6.0
FUD risk
2.0
Coverage12 outlets · 2 tier-1
TechCrunch, Bloomberg, Crunchbase News, Calcalistech
X / Twitter1,800 mentions
@BessemerVP · 1,200 likes
Reddit420 upvotes
r/startups
r/startups, r/venturecapital

Trust check

high

TechCrunch first-party interview with CEO Dov Gertz, specific investor names, specific case-study numbers (4-4.5x yield, single-nanomolar affinity). Unverified but plausible; no FUD flags.

Primary source ↗